Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year,” said ...

Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients ...

Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company focused on marketed products and development candidates, announced its participat ...

Through partnering with neuroscience pharmaceutical companies and by supporting US neurologists and psychiatrists in the diagnosis and optimization of patient care, we are driven to improve ...

Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ: AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that ...

Gal-475 is under clinical development by Neurim Pharmaceuticals and currently in Phase I for Sleep Apnea. According to GlobalData, Phase I drugs for Sleep Apnea have a 96% phase t ...

Explore the essential steps to becoming a neuroscientist, from education to career opportunities in this rewarding field.